Effective siRNA targets screening for human telomerase reverse transcriptase

Figure 1 Inhibitory effects of different siRNA on HepG2 cell growth. HepG2 cells were transfected with siRNA and 48 h after transfection, MTT assays were tested for cell viability. The results were expressed as mean±SD from three determinants.

Figure 2 Inhibition of hTERT mRNA expression in HepG2 cells after 48-h transfection with 100 nmol/L siRNA. A: Electrophoresis of PCR products of hTERT gene and β₂-microglobulin gene in HepG2 cells. Lanes 1-5: HepG2 cells treated with 100 nmol/L siRNA1-siRNA5; Lane C: Cells treated with Lipofectamine^TM2000 only; Lane M: Molecular marker; B: Quantitation of inhibitory percentage of hTERT mRNA in siRNA treated cells. Each level of PCR product of hTERT gene was quantitated and normalized to the level of β₂-microglobulin. The results were expressed as mean±SD from three independent experiments.

Figure 3 Inhibition of hTERT protein expression in HepG2 cells after 72-h transfection with 100 nmol/L siRNA. A: Western-blot analysis of hTERT protein expression in HepG2 cells. Lanes 1-5: HepG2 cells treated with 100 nmol/L siRNA1-siRNA5; Lane C: Cells treated with Lipofectamine^TM2000 only; B: Inhibitory percentage of hTERT protein in siRNA treated cells compared to the cells treated with Lipofectamine^TM2000 alone. Each level of hTERT protein was quantitated and normalized to the level of β-actin. Inhibitory rates were calculated by comparison to cells treated with Lipofectamine^TM2000 alone and results were expressed as mean±SD from two independent experiments.